Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Leukemia ; 15(10): 1564-71, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11587214

ABSTRACT

B cell chronic lymphocytic leukemia (B-CLL) is an incurable clonal disease which shows initial responsiveness to a number of chemotherapeutic drugs. However, in most patients the disease becomes resistant to treatment. Rolipram, a specific inhibitor of phosphodiesterase (PDE) type 4, the PDE predominantly expressed in B-CLL cells, has been shown to induce cAMP-dependent apoptosis in these cells. In the present study, we demonstrate that the extent of rolipram-induced apoptosis is similar to fludarabine-induced apoptosis in vitro. The combination of rolipram and fludarabine results in an enhancement in the number of apoptotic cells compared to apoptosis induced by either agent alone. Second, rolipram suppresses the expression of anti-apoptotic members of the Bcl-2 family and induces the pro-apoptotic protein Bax, thereby shifting the balance between pro- and anti-apoptotic members of the Bcl-2 family towards a pro-apoptotic direction. Finally rolipram-induced apoptosis is caspase-dependent. PDE 4 inhibitors are currently under investigation for chronic obstructive pulmonary disease and asthma in phase III clinical trials showing promising results with tolerable side-effects. In conclusion, by inducing apoptosis, by enhancing apoptosis induced by fludarabine, by suppressing Bcl-2, Bcl-X and by inducing Bax expression, PDE 4 inhibitors may add a new therapeutic option for patients with B-CLL.


Subject(s)
3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitors , Apoptosis/drug effects , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Phosphodiesterase Inhibitors/pharmacology , Proto-Oncogene Proteins c-bcl-2/drug effects , Vidarabine/analogs & derivatives , Aged , Antineoplastic Agents/pharmacology , Caspases/metabolism , Caspases/pharmacology , Cyclic Nucleotide Phosphodiesterases, Type 4 , Down-Regulation , Drug Interactions , Female , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/enzymology , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , Male , Middle Aged , Mitoxantrone/pharmacology , Proto-Oncogene Proteins c-bcl-2/metabolism , Rolipram/pharmacology , Tumor Cells, Cultured/drug effects , Vidarabine/pharmacology
3.
J Pharmacol Exp Ther ; 296(1): 99-105, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11123368

ABSTRACT

Adenosine is a potent anti-inflammatory mediator. Through elevation of endogenous adenosine concentrations the adenosine kinase inhibitor GP515 might serve to down-regulate local inflammatory responses. In the present study we investigated the effect of systemic GP515 in the nonacute model of dextran sulfate sodium (DSS)-induced colitis. The clinical score, colon length, histologic score, colon cytokine production, and spleen weight from mice with DSS-induced colitis (3.5% DSS in drinking water for 11 days) receiving GP515 treatment were determined and compared with untreated control mice. Splenocytes were analyzed for phenotype, interferon-gamma (IFNgamma) production, and CD69 expression. First, GP515 treatment resulted in a significant improvement of clinical score (weight loss, stool consistency, and bleeding) and of histologic score. Second, colon shortening, an indirect parameter for the degree of inflammation, was decreased, consistent with a decreased IFNgamma concentration in the colonic tissue. Third, spleen weight was reduced in GP515-treated DSS mice. And fourth, IFNgamma synthesis and CD69 expression, as a marker for early cell activation, of ex vivo-stimulated splenocytes were suppressed in the GP515-treated DSS mice. These studies show that GP515 is effective in the therapy of DSS-induced colitis. One potential mechanism of action is the suppression of IFNgamma synthesis and CD69 expression. Adenosine kinase inhibition forms a pharmacologic target that should be further investigated for chronic inflammatory bowel disease.


Subject(s)
Adenosine Kinase/antagonists & inhibitors , Colitis/drug therapy , Enzyme Inhibitors/therapeutic use , Gastrointestinal Agents/therapeutic use , Ribonucleosides/therapeutic use , Animals , Antigens, CD/biosynthesis , Antigens, Differentiation, T-Lymphocyte/biosynthesis , Cells, Cultured , Colitis/chemically induced , Colitis/pathology , Colon/metabolism , Colon/pathology , Dextran Sulfate , Female , Flow Cytometry , Interferon-gamma/biosynthesis , Lectins, C-Type , Mice , Mice, Inbred BALB C , Organ Size , Spleen/pathology , Tetradecanoylphorbol Acetate/pharmacology
4.
Clin Cancer Res ; 5(5): 1115-24, 1999 May.
Article in English | MEDLINE | ID: mdl-10353746

ABSTRACT

The two matrix metalloproteinases (MMPs) Mr 72,000 type IV collagenase (MMP-2, gelatinase A) and Mr 92,000 type IV collagenase (MMP-9, gelatinase B) play key roles in tissue remodeling and tumor invasion by digestion of extracellular matrix barriers. We have investigated the production of these two enzymes as well as the membrane-type MMP (MT1-MMP) and the tissue inhibitors of metalloproteinases (TIMPs) TIMP-1 and TIMP-2 in the bone marrow mononuclear cells (BM-MNCs) of patients with acute myeloid leukemia (AML; n = 24), chronic myeloid leukemia (CML; n = 17), myelodysplastic syndromes (MDS; n = 8), and healthy donors (n = 5). Zymographic analysis of BM-MNC-conditioned medium showed that a Mr 92,000 gelatinolytic activity, identified as MMP-9 by Western blotting, was constitutively released from cells of all patients and healthy individuals examined in this study. In contrast, MMP-2 secretion was found to be absent in all samples from healthy donors but present in 8 of 11 (73%) of the samples from patients with primary AML, 7 of 8 (88%) with secondary AML, and only 1 of 5 (20%) cases with AML in remission, indicating MMP-2 to be produced by the leukemic blasts. MMP-2 release was not detected in CML cell-conditioned medium with the exception of two cases, both patients either being in or preceding blast crisis. In MDS, MMP-2 was found in three of eight (38%) of the patients, two of them undergoing progression of disease within 12 months. Quantitative Northern blot analysis in freshly isolated BM-MNCs showed a relatively low constitutive expression of TIMP-1 in all samples, whereas MMP-9 gene transcription was higher in healthy donors and CML samples, than in AML and MDS. Reverse transcriptase-PCR analysis revealed the presence of TIMP-2 mRNA in the majority of MMP-2-releasing BM-MNCs. MT1-MMP expression was present in most samples of patients with MDS or AML but absent in those with secondary AML and CML. Thus, we have shown that BM-MNCs continuously produce MMP-9 and TIMP-1 and demonstrated that leukemic blast cells additionally secrete MMP-2 representing a potential marker for dissemination in myeloproliferative malignancies.


Subject(s)
Biomarkers, Tumor/biosynthesis , Bone Marrow Cells/enzymology , Collagenases/biosynthesis , Gene Expression Regulation, Leukemic , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology , Metalloendopeptidases/biosynthesis , Monocytes/enzymology , Myelodysplastic Syndromes/enzymology , Neoplasm Proteins/biosynthesis , Acute Disease , Adult , Aged , Biomarkers, Tumor/genetics , Blast Crisis/enzymology , Blast Crisis/pathology , Blotting, Northern , Blotting, Western , Cells, Cultured , Collagenases/genetics , Culture Media, Conditioned , Enzyme Induction , Female , Gene Expression Regulation, Enzymologic , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Leukemia, Myeloid/enzymology , Leukemia, Myeloid/pathology , Male , Matrix Metalloproteinase 9 , Matrix Metalloproteinases, Membrane-Associated , Metalloendopeptidases/genetics , Middle Aged , Myelodysplastic Syndromes/genetics , Neoplasm Proteins/genetics , Neoplasms, Second Primary/enzymology , Neoplasms, Second Primary/pathology , Neoplastic Stem Cells/enzymology , Neoplastic Stem Cells/pathology , RNA, Messenger/biosynthesis , RNA, Neoplasm/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction , Tissue Inhibitor of Metalloproteinase-1/biosynthesis , Tissue Inhibitor of Metalloproteinase-1/genetics , Tissue Inhibitor of Metalloproteinase-2/biosynthesis , Tissue Inhibitor of Metalloproteinase-2/genetics , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...